Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-Analysis
Islam AH
Published in Clinical Gastroenterology and Hepatology
Methodology
Systematic review and meta-analysis of randomized controlled trials of pharmacological treatments for severe alcohol-associated hepatitis, with 28-day and longer-term mortality as primary outcomes.
Key Findings
Network and pairwise analyses found corticosteroids plus N-acetylcysteine improved 28-day survival relative to corticosteroids alone in severe alcohol-associated hepatitis (RR 0.35, 95% CI 0.16-0.78), while other pharmacological strategies showed no clear survival benefit.
Conclusions
A survival benefit at 28 days was observed for corticosteroids plus N-acetylcysteine over corticosteroids alone (RR, 0.35; 95% CI, 0.16-0.78).
Limitations
Few trials per comparison, heterogeneous disease-severity definitions and supportive care, and the NAC benefit rests largely on a small number of studies.
Supplements Studied
A survival benefit at 28 days was observed for corticosteroids plus N-acetylcysteine over corticosteroids alone (RR, 0.35; 95% CI, 0.16-0.78).
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.